Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck’s Gardasil encounters FDA roadblock

Executive Summary

Merck received two "complete response" letters to sBLAs for its human papilloma virus vaccine Gardasil for women ages 27 to 45 and for cross-protection, the firm announces June 25. Merck says it will respond to the complete response for older women in July. That application was given priority review in March. However, FDA has indicated data do not support extending the label to include cross-protection. Gardasil was approved in girls and women ages 9 to 26 in 2006 (1"The Pink Sheet," June 12, 2006, p. 3)

You may also be interested in...

FDA expands Gardasil uses, but not users

Merck's Gardasil vaccine for cervical cancer received approval for prevention of vaginal and vulvar cancer caused by human papilloma virus types 16 and 18, FDA announces Sept. 12. The extended indication still applies to the same age range, women nine to 26. In June, the firm received two "complete response" letters for sBLAs seeking approval for women ages 27 to 45 (1"The Pink Sheet," June 30, 2008, In Brief). Gardasil's label has been revised to note that presently available data is insufficient to support use beyond age 26, and information has been added showing that the vaccine does not protect against diseases caused by HPV types excluded from the vaccine

Gardasil Clears FDA, But Dosing May Pose Administrative Challenges

Administration of Merck's recently approved human papillomavirus vaccine Gardasil at the recommended schedule of zero, two and six months may pose a logistical challenge to vaccinating adolescents

Teva’s ‘Skinny Label’ Dispute Edges Toward Supreme Court With Government’s Backing

US Solicitor General urges the Supreme Court to grant Teva's petition, arguing that the Federal Circuit was wrong in ruling that Teva's carved-out labeling for generic carvedilol induced infringement of GlaxoSmithKine's brand product.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts